Clinical trials: Psychological Disorders
Opioid-use Disorder
CBT4CBT for Office Based Buprenorphine
In this Phase II SBIR/STTR project, our Specific Aim will be to determine if the use of CBT4CBT-Buprenorphine leads to clinically significant improved outcomes and increased retention for buprenorphine maintenance patients in a…
- Trial name
- NCT03580902
- Testing
- CBT4CBT-Buprenorphine, Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- CBT4CBT, LLC
Parkinson Disease, Excessive Daytime Somnolence
Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study
Following screening visit and verification of inclusion/exclusion criteria and informed consent, participants will undergo a multiple sleep latency test (MSLT) and polysomnogram (PSG) assessments to confirm eligibility for…
- Trial name
- NCT05056194
- Testing
- Valiloxybate
- Sponsor
- XWPharma
Cognitive Decline
Evaluation of Cognitive State Using Neurosteer EEG System
This is an observational study. Patients who fulfill all inclusion criteria and none of the exclusion criteria will be enrolled in the study, be neurologically evaluated and will go through EEG recordings while listening to an…
- Trial name
- NCT04386902
- Testing
- Neurosteer Aurora system
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Neurosteer Ltd.
Restless Legs Syndrome
Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study
Gabapentin enacarbil (GEn; GSK1838262; HORIZANT), at a dose of 600 mg/day, is currently approved in the United States for the treatment of adults with moderate-to-severe primary Restless Legs Syndrome (RLS).
- Trial name
- CONCORD (NCT01668667)
- Testing
- GSK1838262 600 mg, GSK1838262 450 mg, GSK1838262 300 mg
- Where
- 42 sites in United States
- Volunteers
- 501 people
- Sponsor
- XenoPort, Inc.
Pain, Pain Syndrome
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06072001
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Autism
Prebiotic Intervention for Autism Spectrum Disorders
The purpose of this study is to determine the effect of a prebiotic (BGOS) on gut microbiota and metabolites in children with autism spectrum disorders.
- Trial name
- NCT02720900
- Testing
- B-GOS, Maltodextrin
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- Clasado Limited
Non Restorative Sleep, Sleep Disorder (Disorder)
Sleep Promoting Properties of a Botanical Extract in a Population Complaining From Non-Restorative Sleep (NRS)
The goal of this clinical trial is to evaluate the effect of the Botanical Extract in improving sleep symptoms of nonrestorative sleep (NRS) in healthy adults.
- Trial name
- NCT07085819
- Testing
- Botanical Extract, 125mg, Botanical Extract, 250mg, Botanical Extract, 500mg
- Where
- Ireland
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Kerry Group P.L.C
Schizophrenia
Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia
This is an observational, non-interventional study that will include two cohorts of patients with schizophrenia who initiated maintenance treatment during a schizophrenia-related hospitalisation or during the immediate three…
- Trial name
- NCT03130465
- Where
- 67 sites in France, Germany and 2 more
- Volunteers
- 636 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Attention Deficit Disorder With Hyperactivity
Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD
This is a open-label, single ascending dose, pharmacokinetic, and tolerability study of NFC-1 in Children and Adolescents (Ages 6-17 Years) with ADHD.
- Trial name
- NCT03006367
- Testing
- NFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Major Depressive Disorder
Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder
Escitalopram is the S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake inhibitors (SSRIs) and are used to treat depression in adults.
- Trial name
- NCT00109044
- Testing
- Escitalopram
- Where
- 18 sites in United States
- Volunteers
- 540 people
- Sponsor
- Forest Laboratories
ADHD - Attention Deficit Disorder With Hyperactivity
Brain Stimulation and Attention Control in Children With ADHD
The goal of this clinical trial is to learn if brain stimulation can help children ages 6 to 12 with attention-deficit/hyperactivity disorder (ADHD) improve their attention and self-control.
- Trial name
- NCT07182344
- Testing
- Intermittent Theta Burst Stimulation to Right DLPFC
- Where
- 2 sites in Kazakhstan
- Volunteers
- 40 people
- Sponsor
- Neurolab Plus
Alzheimer's Disease, Dementia
A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)
This study will evaluate acute symptomatic improvements in cognitive performance in healthy elderly participants with mild-to-moderate Alzheimer's disease.
- Trial name
- NCT00874939
- Testing
- MK-0249 7.5 mg, MK-0249 25 mg, Donepezil 5mg
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Dementia With Lewy Bodies (DLB)
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
The purpose of this clinical study is to evaluate the safety and tolerability (side effects) and pharmacokinetics (drug levels in the body) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.
- Trial name
- NCT06815965
- Testing
- neflamapimod
- Where
- 2 sites in France
- Volunteers
- 26 people
- Sponsor
- EIP Pharma Inc
Autism Spectrum Disorder, Sleep Disorder
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
This is a multicenter, open-label study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon in treating sleep disturbances in pediatric and adult participants with ASD.
- Conditions
- Autism Spectrum Disorder, Sleep Disorder, Neurological Disorder, Sleep Disturbance
- Trial name
- NCT05361707
- Testing
- Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Vanda Pharmaceuticals
Sleep Disturbance, Insomnia
A Clinical Trial to Evaluate the Effects of EMF Protection Devices on Sleep and Energy Levels
This study evaluates the effects of a selection of EMF protection devices (Home Harmonizers, Better ZZZs, iCell Chip, Car Harmonizer, Laptop Chip, XL Band, and Device Chips) on sleep quality, sleep quantity, and energy levels in…
- Conditions
- Sleep Disturbance, Insomnia, Fatigue, Electromagnetic Field Exposure
- Trial name
- NCT07746011
- Testing
- EMF Protection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Life Harmony Energies, Inc.
ADHD, Narcolepsy
Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR)
This is a pilot randomized, double-blind, active-controlled, 2-treatment, crossover study to evaluate the PK, user experience and abuse liability of manipulated ADAIR compared to a manipulated commercially-available d-amphetamine…
- Trial name
- NCT04232644
- Testing
- ADAIR 10mg IR capsules, Crushed d-amphetamine sulfate IR tablets
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vallon Pharmaceuticals, Inc.
Major Depressive Disorder
Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers
The objectives of this study were to examine the cardiovascular sensitivity to oral tyramine after establishment of steady state with CX157 Modified Release (MR) Tablets, 125 mg administered twice per day (BID) in healthy…
- Trial name
- CX157-112 (NCT01633437)
- Testing
- CX157
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- CeNeRx BioPharma Inc.
Generalized Anxiety Disorder
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
- Trial name
- NCT00236067
- Testing
- Gabitril
- Where
- 21 sites in United States
- Volunteers
- 440 people
- Sponsor
- Cephalon
Alzheimer Disease, MCI
Validation Study of a New Digital Treatment Test
Oculomotor behavior and cognitive processing of visual information are intimately connected. AD patients show ocular movement problems.
- Trial name
- NCT04897464
- Testing
- BGaze therapy Alzheimer
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Braingaze
Neurocognitive Disorders, Mild, Cognitive Impairment, Mild
Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders
This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such…
- Conditions
- Neurocognitive Disorders, Mild, Cognitive Impairment, Mild, Depression Mild, Apathy
- Trial name
- NCT07237009
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- KompanionCare SAS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.